Skip to content

Comparing Triamcinolone Acetonide Mucoadhesive Films With Licorice Mucoadhesive Films

Comparison of Triamcinolone Acetonide Mucoadhesive Film With Liquorice Mucoadhesive Film On Radiotherapy-Induced Oral Mucositis: A Randomized Double-Blinded Clinical Trial

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02075749
Enrollment
60
Registered
2014-03-03
Start date
2013-05-31
Completion date
2014-02-28
Last updated
2014-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mucositis

Keywords

irradiation, mucositis, triamcinolone acetonide, licorice, mucoadhesive film

Brief summary

Abstract: Background: Complementary and alternative medicine (CAM) had proven efficacy in pain relief, correction of nutritional status and improving the performance status. However, lack of standardization is the major obstacle for any scientific evaluation of any CAM trial. Mucositis is a major complication of irradiation in head and neck (H&N) tumors, the addition of chemotherapy to irradiation may enhance this dose limiting problem. Licorice is a strong demulcent that had been effectively used in treatment of peptic ulcer. The main purpose of this study was to compare the therapeutic safety and efficacy of T. and L. mucoadhesive films on oral mucositis in terms of pain control and/or ulcer treatment. Methods and Materials: the study was a double-blind, randomized prospective trial of two types of mucoadhesive films in the management of oral mucositis occurred during head and neck cancer ( HNC ) radiotherapy. oral mucositis was assessed using a quantitative scale (WHO scales) and symptoms were assessed using visual analogue scales (VAS). 60 patients were enrolled in the study; there were 30 patients in the Triamcinolone (T) and 30 in the Licorice (L) group. In the T- group, patients received triamcinolone acetonide mucoadhesive films containing 1mg of the drug and patients in the L- group received licorice mucoadhesive films, an herbal agent. Data were collected at baseline, then twice a week for 4 weeks.

Interventions

DRUGTriamcinolone Acetonide
DRUGlicorice mucoadhesive films

30 patients received licorice mucoadhesive films

Sponsors

Isfahan University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* over 18 years of age * men and nonpregnant women * women of childbearing age who were non-pregnant by pregnancy test and and using medically prescribed contraceptive * no previous radiation therapy applied in the head and neck * medically fit for a course of radical radiotherapy * an ability to remain in the study for its entire duration

Exclusion criteria

* pregnant women * women of childbearing potential in whom medically prescribed birth control was not used * concurrent chemotherapy * history of heavy alcohol or drug abuse judged to be important by the investigator - concomitant therapy with an investigational drug, or cancer chemo therapeutics or immunosuppressive medications * sensitivity or intolerance to triamcinolone or licorice, lactose or similar formulations * inability to provide informed consent * actively bleeding gastric ulcer, severe esophageal reflux * major surgery, trauma or burns in the preceding 4 weeks * clinically significant hepatic, neurologic, endocrine, or other systemic disease-making implementation of the protocol or results difficult.

Design outcomes

Primary

MeasureTime frameDescription
pain score4 weeksat the end of each consecutive week the pain score was recorded.

Secondary

MeasureTime frameDescription
mucositis grade4 weeksthe grading of mucositis was assessed and recorded at the end of each week.

Other

MeasureTime frameDescription
quality of life4 weekspatient's satisfaction and ability to perform social activity were assessed at the end of trial.

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026